Small Molecules
30 September 2014
OncoMed Pharmaceuticals Announces Selection of First Small Molecule Product Candidate Targeting the Wnt Pathway Under Collaboration With Bayer Pharma AG30 September 2014
CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer30 September 2014
FDA Approves RELISTOR® Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain29 September 2014
FDA Approves NeuroGenetic Pharmaceuticals Application to Begin Clinical Trials for Its NGP 555 Compound to Treat and Prevent Alzheimer’s Disease29 September 2014
GSK announces overall survival results from phase III BREAK-3 study of Tafinlar® (dabrafenib) in patients with BRAF V600E-mutant metastatic melanoma29 September 2014
Allergan Announces FDA Approves Revised Indication for OZURDEX® (dexamethasone intravitreal implant) 0.7 mg for the Treatment of Diabetic Macular Edema29 September 2014
Acasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C29 September 2014
CymaBay Completes Enrollment in its Phase 2b Study of Arhalofenate in Patients with Gout29 September 2014
ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer29 September 2014
Tonix Pharmaceuticals Reports Top Line Results From Phase 2b BESTFIT Trial of TNX-102 SL in Patients With Fibromyalgia29 September 2014
Acura Pharmaceuticals Hydrocodone Bitartrate With Acetaminophen Tablets Meet Clinical Endpoints29 September 2014
Puma Biotechnology Announces Positive Initial Results from PB272 Phase II Trial in HER2 Mutated Non-Small Cell Lung Cancer29 September 2014
CHMP Announces Positive Opinion for REZOLSTA™, a New Once-Daily, Fixed-Dose HIV Therapy Combining Darunavir and Cobicistat29 September 2014
Phase 2b TARGET Trial Results Show Improved Survival in Adenocarcinoma Non-Small Cell Lung Cancer Patients Treated With Endocyte’s Vintafolide29 September 2014
Ipsen Presents Preliminary Results of Exploratory Proof-of-Concept Study with Tasquinimod in Four Advanced Tumor Types at the ESMO 2014 Congress29 September 2014
Data from Ongoing Phase 2 Studies of Rucaparib in Ovarian Cancer Demonstrate Safety and Clinical Activity, Validate Differentiated Strategy29 September 2014
AZD9291 Shows Durable Clinical Response in Patients with Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer at the ESMO 2014 Congres29 September 2014
Ignyta Announces Interim Data from RXDX-101 Phase I Clinical Trial at 2014 ESMO CongressNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports